Step 2 regimens in hypertension. An assessment

Area of Science:

• Cardiology
• Pharmacology

Background:

• Essential hypertension management often requires combination therapy when initial treatments are insufficient.
• Thiazide diuretics like hydroflumethiazide are common first-line agents for elevated blood pressure.

Purpose of the Study:

• To compare the efficacy and safety of second-line combination therapies for hypertension.
• To evaluate hydroflumethiazide combined with reserpine, methyldopa, or propranolol in patients with resistant hypertension.

Main Methods:

• A single-blind clinical trial involving 59 patients with uncontrolled elevated blood pressure (BP).
• Patients received hydroflumethiazide plus either reserpine, methyldopa, or propranolol hydrochloride for nine weeks.
• Diastolic BP was monitored to assess treatment response.

Main Results:

• All 20 patients on reserpine-hydroflumethiazide achieved diastolic BP below 90 mm Hg.
• 13 of 19 patients on methyldopa-hydroflumethiazide and 16 of 20 on propranolol-hydroflumethiazide reached the target BP.
• Adverse reactions were only reported in the methyldopa group; laboratory values remained largely unchanged.

Conclusions:

• Hydroflumethiazide in combination with reserpine, methyldopa, or propranolol is effective for managing resistant hypertension.
• The reserpine-hydroflumethiazide combination demonstrated superior efficacy and offered advantages in dosage convenience and cost.
• All evaluated combination therapies showed comparable safety profiles, with methyldopa being the exception due to reported adverse events.